Literature DB >> 29025775

A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR.

Sadichhya Lohani1, Jon Golenbiewski1, Abhishek Swami1,2, Alexandra Halalau1,3.   

Abstract

A 57-year-old woman presented with swelling and thickening of the skin of the lower extremities. Three months prior to presentation, patient had MRI with gadolinium as part of an evaluation for suspected pancreatic malignancy. Creatinine levels at the time of gadolinium exposure were 0.9-1.2 mg/dL, with a corresponding estimated glomerular filtration rate of 64 mL/min/1.73m2 by modification of diet in renal disease equation. Twenty-four-hour urine creatinine clearance was performed as an outpatient following development of symptoms. This revealed a creatinine clearance of 23 mL/min, suggestive of advanced chronic kidney disease despite an estimated glomerular filtration rate of 64 mL/min/1.73m2 Skin biopsy was positive for sclerosing dermopathy. These findings, in addition to the temporal association with gadolinium exposure, led to the diagnosis of nephrogenic systemic fibrosis. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  contraindications and precautions; dermatology; renal system

Mesh:

Substances:

Year:  2017        PMID: 29025775      PMCID: PMC5652398          DOI: 10.1136/bcr-2017-221016

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

2.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

3.  The revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population.

Authors:  Ulf Nyman; Anders Grubb; Anders Larsson; Lars-Olof Hansson; Mats Flodin; Gunnar Nordin; Veronica Lindström; Jonas Björk
Journal:  Clin Chem Lab Med       Date:  2014-06       Impact factor: 3.694

4.  Nephrogenic systemic fibrosis in a gadolinium-naïve patient: successful treatment with oral sirolimus.

Authors:  Christopher Ross; Nicholas De Rosa; Gillian Marshman; David Astill
Journal:  Australas J Dermatol       Date:  2014-10-21       Impact factor: 2.875

5.  Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium.

Authors:  Krista N Larson; Amy L Gagnon; Melissa D Darling; James W Patterson; Thomas G Cropley
Journal:  JAMA Dermatol       Date:  2015-10       Impact factor: 10.282

Review 6.  Estimating GFR prior to contrast medium examinations--what the radiologist needs to know!

Authors:  Ulf Nyman; Jonas Björk; Sten-Erik Bäck; Gunnar Sterner; Anders Grubb
Journal:  Eur Radiol       Date:  2015-05-28       Impact factor: 5.315

7.  Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis.

Authors:  Severin Läuchli; Claudia Zortea-Caflisch; Frank O Nestle; Günter Burg; Werner Kempf
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

8.  UV-A1 therapy for nephrogenic systemic fibrosis.

Authors:  Kien T Tran; Heidi B Prather; Clay J Cockerell; Heidi Jacobe
Journal:  Arch Dermatol       Date:  2009-10

Review 9.  Treatment of nephrogenic systemic fibrosis: limited options but hope for the future.

Authors:  Douglas R Linfert; Jane O Schell; Derek M Fine
Journal:  Semin Dial       Date:  2008-01-23       Impact factor: 3.455

10.  Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents.

Authors:  Henrik S Thomsen; Peter Marckmann; Vibeke B Logager
Journal:  Cancer Imaging       Date:  2007-09-24       Impact factor: 3.909

View more
  7 in total

1.  Is it time to relax nephrogenic systemic fibrosis guidelines and safely offer magnetic resonance imaging to more patients?

Authors:  Saif Al-Chalabi; Constantina Chrysochou; Philip A Kalra
Journal:  Quant Imaging Med Surg       Date:  2019-11

2.  Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: PRO.

Authors:  Roger A Rodby
Journal:  Kidney360       Date:  2020-12-03

3.  Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration.

Authors:  E Kanal; T J Patton; I Krefting; C Wang
Journal:  AJNR Am J Neuroradiol       Date:  2020-02-27       Impact factor: 3.825

4.  Use of Gadolinium in Individuals with Reduced Kidney Function.

Authors:  Kambiz Kalantari; Sundararaman Swaminathan
Journal:  Clin J Am Soc Nephrol       Date:  2021-01-11       Impact factor: 10.614

Review 5.  Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.

Authors:  Jeffrey C Weinreb; Roger A Rodby; Jerry Yee; Carolyn L Wang; Derek Fine; Robert J McDonald; Mark A Perazella; Jonathan R Dillman; Matthew S Davenport
Journal:  Kidney Med       Date:  2020-11-10

Review 6.  Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials.

Authors:  Ben Sprangers; Mark A Perazella; Stuart M Lichtman; Mitchell H Rosner; Kenar D Jhaveri
Journal:  Kidney Int Rep       Date:  2022-06-15

7.  Overlapping roles of NADPH oxidase 4 for diabetic and gadolinium-based contrast agent-induced systemic fibrosis.

Authors:  Francesca Bruno; Joshua DeAguero; Catherine Do; Doug Yoon Lee; Chunyan Tan; G Patricia Escobar; Brent Wagner
Journal:  Am J Physiol Renal Physiol       Date:  2021-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.